Skip to main content

Table 2 COPD-Related Adjusted Multivariate Outcomes and Unadjusted Outcomes in the Follow-up Period by Cohort

From: Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease

Adjusted Outcomes

 

Adjusted Hazard Ratio: TIO+FSC vs TIO (reference cohort: TIO)

95% CI

P value

Any exacerbation

0.772

(0.641, 0.930)

0.007

   Severe

0.622

(0.328, 1.180)

0.146

   Moderate

0.763

(0.646, 0.949)

0.013

COPD-related hospital/emergency room visit

0.742

(0.511, 1.078)

0.118

   Hospitalization

0.681

(0.400, 1.159)

0.157

   Emergency room visit

0.807

(0.504, 1.293)

0.373

Unadjusted Outcomes: Rate per 100 Person-Years

 

TIO Alone

TIO+FSC

P value

 

n = 2481

n = 852

 

Any exacerbation

95.58

75.38

0.003

   Severe

7.86

5.06

0.171

   Moderate

88.65

69.74

0.004

COPD-related hospital/emergency room visit

21.29

15.79

0.070

   Hospitalization

11.14

7.43

0.667

   Emergency room visit

12.63

9.90

0.213

  1. P values < 0.05 are bolded.
  2. CI = confidence interval